By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Kyowa Hakko Kirin 

Ohtemachi Building 5F
1-6-1 Ohtemachi, Chiyoda-ku
Tokyo    100-8185  Japan
Phone: 81-3-3282-0007 Fax: 81-3-3284-1968



Company News
Kyowa Hakko Kirin And Bristol-Myers Squibb (BMY) Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab And Opdivo (Nivolumab) In Advanced Solid Tumors In The U.S. 7/30/2015 12:48:04 PM
Syndax Pharmaceuticals Inc. Snags $125 Million Deal With Kyowa Hakko Kirin 1/8/2015 7:34:35 AM
Ono Pharmaceutical Company, Ltd., Bristol-Myers Squibb Company (BMY), And Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (Nivolumab) And Mogamulizumab In Advanced Solid Tumors 12/10/2014 9:19:38 AM
Pfizer (PFE) And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study 9/30/2014 10:19:02 AM
Pfizer (PFE), Kyowa Hakko Kirin Team Up On Immuno-Oncology Combination Study 9/30/2014 6:05:52 AM
ArQule, Inc. (ARQL) Announces Commencement Of Phase 3 Clinical Trial With Tivantinib In Hepatocellular Carcinoma By Partner Kyowa Hakko Kirin In Japan 2/4/2014 9:46:24 AM
The NovAliX/Kyowa Hakko Kirin Alliance Will Commence A Fragment-Based Drug Discovery Project Targeting An Important Protein/Protein Interaction 11/18/2013 10:49:47 AM
Ultragenyx Pharmaceuticals Announces the Presentation of Data From a Single Dose Phase 1 Study, Conducted by Kyowa Hakko Kirin, of KRN23 in X-linked Hypophosphatemia (XLH) in Adults 10/7/2013 9:45:31 AM
Abstral® , Manufactured and Packaged by Recipharm AB for Kyowa Hakko Kirin, Has Been Approved in Japan 9/23/2013 8:22:40 AM
Activiomics Extends Research Agreement With Kyowa Hakko Kirin as Part of Its Strategic Partnership With BioFocus DPI 9/19/2013 9:40:30 AM